FDA approves Abraxane for NSCLC

FDA approved an sNDA from Celgene Corp. (NASDAQ:CELG) for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The albumin stabilized nanoparticle formulati...